{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:29:23Z","timestamp":1793755763125,"version":"4.6.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":158,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2026.100597","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:09:24Z","timestamp":1781309364000},"page":"100597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rare CNS manifestation of high-risk CLL with excellent response to triplet targeted therapy"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0530-2963","authenticated-orcid":false,"given":"Anusha","family":"Swaminathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrinidhi","family":"Nathany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aastha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishita B","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paritosh","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakriti","family":"kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lrr.2026.100597_bib0001","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3324\/haematol.2015.136556","article-title":"Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia","volume":"101","author":"Strati","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.lrr.2026.100597_bib0002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s13256-024-04639-4","article-title":"Central nervous system involvement in chronic lymphocytic leukemia: a case report and review of literature","volume":"18","author":"Qin","year":"2024","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.lrr.2026.100597_bib0003","article-title":"Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL","author":"Chatzikonstantinou","year":"2025","journal-title":"Blood Adv."},{"issue":"25","key":"10.1016\/j.lrr.2026.100597_bib0004","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lrr.2026.100597_bib0005","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.lrr.2026.100597_bib0006","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/bloodadvances.2022009040","article-title":"Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL","volume":"7","author":"Griffin","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.lrr.2026.100597_bib0007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/bjh.14387","article-title":"Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients","volume":"176","author":"Wanquet","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.lrr.2026.100597_bib0008","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/TP53 mutation","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lrr.2026.100597_bib0009","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in treatment-na\u00efve chronic lymphocytic leukemia enriched for high-risk disease","volume":"43","author":"Davids","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.lrr.2026.100597_bib0010","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: long-term results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lrr.2026.100597_bib0011","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bjh.17984","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia in patients with TP53 aberrations: pooled analysis from four clinical trials","volume":"196","author":"Allan","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.lrr.2026.100597_bib0012","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1007\/s00277-025-06498-5","article-title":"Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: results of the NAOS study","volume":"104","author":"Quinquenel","year":"2025","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.lrr.2026.100597_bib0013","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4274\/tjh.2017.0313","article-title":"Successful treatment of chronic lymphocytic leukemia with multifocal CNS involvement using ibrutinib","volume":"35","author":"Christoforidou","year":"2018","journal-title":"Turk. J. Haematol."},{"issue":"21","key":"10.1016\/j.lrr.2026.100597_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110521","article-title":"Acalabrutinib as consolidation or maintenance therapy in primary CNS lymphoma: case report and literature review","volume":"26","author":"Allison","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.lrr.2026.100597_bib0015","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.3324\/haematol.2018.213157","article-title":"Venetoclax penetrates cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with CNS involvement","volume":"104","author":"Reda","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.lrr.2026.100597_bib0016","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000523858","article-title":"Venetoclax: a novel therapeutic agent for CLL with CNS involvement","volume":"15","author":"Karbhari","year":"2022","journal-title":"Case Rep. Oncol."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:11:09Z","timestamp":1793754669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048926000373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":16,"alternative-id":["S2213048926000373"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100597","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rare CNS manifestation of high-risk CLL with excellent response to triplet targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100597","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100597"}}